Gilead Sciences (NASDAQ:GILD) gains attention within the nasdaq composite following disclosure and steady performance signals ...

Wall Street is mired in another panic over AI. And we contrarians are here for it. Our play? This closed end fund yielding ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 11:10 AM ESTCompany ParticipantsJohanna Mercier - Chief ...

The inaugural direct-to-consumer campaign for the injectable drug debuted earlier this year, centering around a TV ad featuring a remake of Ciara and Missy Elliott’s 2004 hit song “1, 2 Step”—now ...

The VDH has not answered questions about how much money it erroneously overbilled a pharmaceutical manufacturer and may have to pay back, despite the issue triggering significant cuts to HIV services.

Poor shooting and untimely fouls ultimately doomed the Bowling Green Christian Academy’s varsity boys basketball team on ...

In this week's episode of the CNBC Changemakers and Power Players podcast, CNBC Senior Media and Tech Reporter Julia Boorstin spoke with Johanna Mercier, Chief Commercial & Corporate Affairs Officer ...

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...

Merck's blockbuster immunotherapy Keytruda, which generates nearly half of its total revenue, is scheduled to lose U.S. patent protection in 2028, opening the door to lower-cost generic competition.

It's designed to take the place of complicated, multiple drug regimens that many people with HIV need to follow. And it's ...

At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.

February 2026 saw a major biopharma acquisition, four key buyouts, and licensing deals in antibodies, small molecules, and ...